Tanguler Tolga's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Oct 3, 2025
- Accession no.
- 0001735276-25-000115
- Filed
- Oct 3, 2025
- Trade date
- Oct 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 13 non-derivative transactions and 0 derivative transactions. Open-market sales total $635.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tanguler TolgaCIK 0001849458 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | Common Stock | AGrant or awardAcquired | +2,851 | $0.00 | $0 | 28,843 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −55 | $446.53 | −$24,559.15 | 28,788 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −27 | $447.92 | −$12,093.84 | 28,761 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −86 | $448.77 | −$38,594.22 | 28,675 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −119 | $449.79 | −$53,525.01 | 28,556 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −260 | $450.81 | −$117,210.6 | 28,296 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −159 | $451.86 | −$71,845.74 | 28,137 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −319 | $452.69 | −$144,408.11 | 27,818 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −157 | $453.77 | −$71,241.89 | 27,661 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −117 | $454.84 | −$53,216.28 | 27,544 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −35 | $455.82 | −$15,953.7 | 27,509 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −70 | $457.43 | −$32,020.1 | 27,439 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −1 | $457.64 | −$457.64 | 27,438 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.